Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

              Author:Sacca, Francesco   Costabile, Teresa   Signoriello, Elisabetta   Lauro, Francesca   Altieri, Manuela   Ziello, Antonio Rosario   d'Ambrosio, Alessandro   Bisecco, Alvino   Maniscalco, Giorgia Teresa   Bonavita, Simona   Gallo, Antonio   Brescia Morra, Vincenzo   Lus, Giacomo   Russo, Cinzia Valeria   

              Session Name:P3: MS Technology, Digital Tools and Artificial Intelligence  

              Topic:MS and Inflammatory Disease  

              Program Number:P3.010  

              Author Institution:University Federico II, Napoli, Italy  University of Campania “Luigi Vanvitelli”, Napoli, Italy  “A. Cardarelli” Hospital, Napoli, Italy  University of Campania “Luigi Vanvitelli”, Naples, Italy  

              Cognitive Function Remains Associated with Global Functional Impairment in Profound Dementia due to Alzheimer's Disease and Dementia with Lewy Bodies

              Author:Rampalli, Ihika   Pavlik, Valory   Yu, Melissa   Bishop, Jeffrey   Lin, Chi-Ying   

              Session Name:P6: Aging and Dementia: Innovation in Cognitive and Functional Assessments  

              Topic:Aging and Dementia  

              Program Number:P6.011  

              Author Institution:Baylor College of Medicine, Houston, TX  

              Trofinetide for the treatment of Rett syndrome: an open-label study in girls 2 to 4 years of age

              Author:Percy, Alan   Ryther, Robin   Marsh, Eric   Feyma, Timothy   Lieberman, David   Neul, Jeffrey   Benke, Timothy   Glaze, Daniel   Berry-Kravis, Elizabeth   Ananth, Amitha   Buhrfiend, Colleen   Stankovic, Srdjan   Bishop, Kathie   Darwish, Mona   Youakim, James   

              Session Name:P13: Child Neurology and Developmental Neurology: Cerebral Palsy/Autism Spectrum Disorder/Neurodevelopmental Disorders  

              Topic:Child Neurology and Developmental Neurology  

              Program Number:P13.005  

              Author Institution:University of Alabama At Birmingham, Birmingham, AL  Washington University School of Medicine, St Louis, MO  Children’s Hospital of Philadelphia, Philadelphia, PA  Gillette Children'S Specialty Healthcare, Saint Paul, MN  Boston Children's Hospital, Boston, MA  Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN  Children’s Hospital of Colorado/University of Colorado School of Medicine, Aurora, CO  Texas Children’s Hospital/Baylor College of Medicine, Houston, TX  Rush University Children’s Hospital, Chicago, IL  Rush Univeristy Medical Center, Chicago, IL  Acadia Pharmaceuticals Inc., Princeton, NJ  Acadia Pharmaceuticals Inc., San Diego, CA  

              Treatment with trofinetide shows benefit compared to placebo for the ability to communicate in individuals with Rett syndrome: a secondary analysis of the LAVENDER study

              Author:Neul, Jeffrey   Percy, Alan   Benke, Timothy   Berry-Kravis, Elizabeth   Glaze, Daniel   Peters, Sarika U   Marsh, Eric   An, Di   Bishop, Kathie   Youakim, James   

              Session Name:P13: Child Neurology and Developmental Neurology: Cerebral Palsy/Autism Spectrum Disorder/Neurodevelopmental Disorders  

              Topic:Child Neurology and Developmental Neurology  

              Program Number:P13.006  

              Author Institution:Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN  University of Alabama At Birmingham, Birmingham, AL  Children’s Hospital of Colorado/University of Colorado School of Medicine, Denver, CO  Rush University Medical Center, Chicago, IL  Texas Children’s Hospital/Baylor College of Medicine, Houston, TX  Children's Hospital of Philadelphia, Philadelphia, PA  Acadia Pharmaceuticals Inc., San Diego, CA  Acadia Pharmaceuticals, Inc., San Diego, CA  

              Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Adults With Lennox-Gastaut Syndrome: Post-Hoc Analysis of Dose Effects From a Phase 3 Trial Rationale

              Author:Bishop, Kim   Isquith, Peter   Knupp, Kelly   Sullivan, Joseph   Nabbout, Rima   Gil-Nagel, Antonio   Scheffer, Ingrid   Auvin, Stéphane   Cross, J Helen   Guerrini, Renzo   Roth, Robert   Gioia, Gerard   Lothe, Amélie   Polega, Shikha   

              Session Name:P11: Epilepsy/Clinical Neurophysiology (EEG): ASMs Clinical Trial 1  

              Topic:Epilepsy/Clinical Neurophysiology (EEG)  

              Program Number:P11.001  

              Author Institution:Global Pharma Consultancy, LLC, Muncy, PA  Global Pharma Consultancy, LLC  Boston Children’s Hospital, Harvard Medical School, Boston, MA  Children's Hospital Colorado, Aurora, CO  University of California San Francisco, Benioff Children’s Hospital, San Francisco, CA  Reference Centre for Rare Epilepsies, Hôpital Universitaire Necker-Enfants Malades, APHP, Member of EPICARE, Institut Imagine, Université Paris Cité, Paris, France  Hospital Ruber Internacional, Madrid, Spain  University of Melbourne, Austin Hospital and Royal Children’s Hospital, Florey Institute and Murdoch Children’s Research Institute, Heidelberg, Australia  Robert Debré University Hospital, APHP, Université de Paris, Institut Universitaire de France (IUF), Paris, France  UCL NIHR BRC Great Ormond Street Institute of Child Health, London, United Kingdom  Anna Meyer Children's Hospital, University of Florence, Milan, Italy  Dartmouth-Hitchcock Medical Center, Lebanon, NH  Children’s National Health System, Rockville, MD  Zogenix International (now a part of UCB), Maidenhead, United Kingdom  Zogenix, Inc. (now a part of UCB), Emeryville, CA